Valbenazine Linked to Improved Antipsychotic Adherence in Tardive Dyskinesia
Initiating VMAT2 inhibitor treatment may help patients maintain essential psychiatric medication regimens.
1Study Findings on Adherence
A retrospective cohort study of Medicare claims indicates that initiating valbenazine for tardive dyskinesia may reduce antipsychotic discontinuation. Among patients with schizophrenia or other psychotic spectrum disorders, valbenazine use was associated with an 18% lower risk of stopping all antipsychotics for at least 60 days, supporting better long-term psychiatric treatment continuity.
2Clinical Context and Mechanism
Valbenazine is a VMAT2 inhibitor approved in 2017 to treat repetitive movements associated with tardive dyskinesia. By addressing these involuntary movements, the drug may help patients remain on their primary antipsychotic medications. Maintaining this stability is crucial, as medication discontinuation often increases the risk of psychiatric relapse and hospitalization.
3Patient Cohort Characteristics
Researchers analyzed data from 66,348 Medicare beneficiaries diagnosed with tardive dyskinesia between 2016 and 2023. The average patient age was 62.9 years, with 60.8% female participants. Over half of the cohort suffered from psychotic spectrum disorders, while 38.6% were treated for mood disorders, reflecting a diverse population with complex mental health needs.
4Diagnostic Subgroup Variations
The study noted significant differences between patient subgroups. While psychotic spectrum disorder patients showed clear benefits, the overall cohort results were less pronounced. Researchers suggest this reflects varying clinical needs, as antipsychotics are foundational for psychotic disorders, whereas mood disorder patients may have more flexible alternative treatment options available to them.
5Methodological Sensitivity Analysis
While the primary analysis focused on a 60-day gap in medication, a sensitivity analysis using a 30-day threshold reached statistical significance. This suggests a stronger association between valbenazine initiation and antipsychotic persistence when shorter gaps in coverage are measured. These findings help clarify the real-world impact of VMAT2 inhibitors on treatment.
6Healthcare Utilization Impact
Non-persistence with antipsychotic therapy is linked to increased emergency department visits and inpatient hospitalizations. In the study group, 38.2% had an inpatient stay and 60.9% visited the emergency department in the year prior to diagnosis. Reducing discontinuation rates could potentially lower these downstream healthcare burdens for vulnerable psychiatric patient populations.
7Study Limitations Acknowledged
The researchers noted that the study is limited by its observational design and potential for residual confounding. Because the data relies on Medicare claims, it does not capture clinical severity, specific treatment rationales, or actual patient medication adherence. These factors remain important variables that could influence the observed outcomes in future research.
8Clinical Implications and Future
Presented at the Neuroscience Education Institute Fall Congress, the data highlights the importance of managing tardive dyskinesia to support psychiatric stability. Future studies could further explore real-world persistence across different demographics. For clinicians, these findings provide a rationale for integrating valbenazine early to facilitate essential maintenance therapy for their patients.